RPG LIFE SCIENCES LTD.

RPG Life Sciences reported strong unaudited financial results for Q1 FY27, with revenue from operations increasing 15.8% year-on-year to ₹195.7 crore. EBITDA grew 17.9% to ₹48.0 crore, and the EBITDA margin expanded by 40 basis points to 24.5%. The Domestic Formulations business outperformed the Indian pharma market, growing 14.8% against the market's 11.6%, leading the company to enter the 'Top 50 Indian Pharma Companies'. International Formulations registered 7.7% growth, and the API business saw a significant 35.6% increase. Managing Director Ashok Nair emphasized the strong start, market-beating performance, and strategic focus on international expansion and API operations for sustained long-term growth.

RPG Life Sciences Ltd announced its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The Board of Directors approved these results during a meeting held on July 28, 2026. The limited review reports from the statutory auditors, SRBC & CO LLP, were also enclosed. The company followed Indian Accounting Standard 34 for interim financial reporting. The filing details the process and confirmation of the results' accuracy based on the review.

RPG Life Sciences posted consolidated revenue from operations of ₹195.69 Cr for Q1 FY27 (quarter ended June 30, 2026), up 15.9% YoY (₹168.92 Cr) and 10.6% QoQ (₹176.89 Cr). Consolidated PAT came in at ₹30.76 Cr, up 17.0% YoY (₹26.29 Cr) and a more modest 2.9% QoQ (₹29.90 Cr) — the YoY print is the primary signal here since profit growth outpaced revenue growth, pointing to margin expansion rather than a one-off. Standalone tells an almost identical story (PAT ₹30.57 Cr, EPS ₹18.49 vs consolidated EPS ₹18.60), so the small consolidation delta from the newly formed subsidiary RPG Active Pharma Limited is not yet material to the group numbers. On margins, operating profitability (EBITDA/revenue) improved to roughly 22.1% from ~21.0% a year ago and ~19.2% last quarter, while the net margin held broadly flat at 15.35% (15.1% YoY, 15.8% QoQ) as tax incidence normalised (effective tax rate ~25.8% this quarter vs ~25.8% YoY). Cost of materials consumed (₹37.68 Cr) and employee benefits expense (₹37.76 Cr) grew slower than revenue, the main driver of the operating-margin gain; finance costs rose sharply in percentage terms (₹0.63 Cr vs ₹0.13 Cr YoY) though off a small base, likely tied to working-capital or subsidiary-related funding. There is no consensus or brokerage estimate on record for this stock — it carries no visible formal analyst coverage, so vsStreet is unknown rather than a miss/beat call. Similarly, the company has issued no formal forward guidance in our records or in a web search, so the quarter cannot be graded against a stated management target; management's own press commentary on this result had not been separately released as of this filing. Corporate context this quarter includes the Board approving the unaudited Q1 results on July 28, 2026, the 19th AGM held July 23, 2026, a BRSR sustainability filing, and a July 13, 2026 tie-up with Archerchem to launch Naprosyn ES in India — a new-launch item that is a forward revenue lever rather than a driver of this quarter's print. The Board's December 2025 approval to transfer the API division into wholly-owned subsidiary RPG Active Pharma Limited remains pending regulatory sign-off and is the main structural item to track into subsequent quarters, since it will reshape the standalone/consolidated split once completed.

RPG Life Sciences Ltd has announced that its Board of Directors will convene on July 28, 2026. The primary agenda items include the consideration and approval of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with taking on record the Limited Review Report. Concurrently, the company has implemented a trading window closure for its designated persons and their immediate relatives, effective from July 1, 2026, until 48 hours post the public announcement of the financial results.

RPG Life Sciences (RPG LS) has partnered with Archerchem Healthcare to launch Naprosyn ES, a combination of Naproxen and Esomeprazole, for the first time in India. This product offers an effective anti-inflammatory solution with gastro-protection, addressing a significant unmet need for patients requiring long-term NSAID therapy, especially those at risk of gastrointestinal complications. RPG LS will exclusively market and distribute the product nationwide, while Archerchem will be the exclusive supplier. The launch leverages RPG LS's R&D-driven approach, strong brand recall of Naprosyn, and extensive distribution network, aligning with its strategy to build a differentiated portfolio in chronic therapy segments. The co-developed formulation aims to improve patient compliance and enable safer long-term pain management.

RPG Life Sciences Ltd has informed the stock exchanges about dispatching letters to shareholders whose email addresses are not registered. These letters provide the web link to the Annual Report for FY 2025-26, in compliance with SEBI Listing Regulations. The 19th Annual General Meeting (AGM) is scheduled for July 23, 2026, via Video Conferencing. The company also reminded shareholders holding physical securities to update KYC details, including PAN, address, bank details, and nomination, to ensure eligibility for payments like dividends. Failure to update KYC may result in payments being made only through electronic mode.

RPG Life Sciences Ltd has submitted its Business Responsibility and Sustainability Report 2026 as part of its Annual Report for the financial year 2025-26. This filing, made pursuant to SEBI regulations, includes the Notice of the Nineteenth Annual General Meeting (AGM) scheduled for July 23, 2026, to be held via Video Conferencing. The report highlights the company's commitment to 'Accelerate Intelligence, Embrace Excellence' within the evolving pharmaceutical landscape, focusing on embedding intelligence across research, manufacturing, and customer engagement. The Annual Report, containing the BRSR and AGM notice, is available on the company's website and will be sent electronically to shareholders. The company emphasizes its core values of trust, innovation, and 'Hello Happiness', aiming for sustainable growth and stakeholder well-being.

RPG Life Sciences Ltd has issued a notice for its 19th Annual General Meeting (AGM) to be held on Thursday, July 23, 2026, at 3:00 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company is also submitting its Annual Report for the financial year 2025-26, which includes the Business Responsibility and Sustainability Report, as per SEBI regulations. The Annual Report and AGM notice are being sent electronically to members and are also available on the company's website. The notice details the process for remote e-voting and participation in the AGM via VC/OAVM.

RPG Life Sciences Ltd has announced that its Nineteenth Annual General Meeting (AGM) will be held on Thursday, July 23, 2026, at 3:00 p.m. IST via Video Conferencing. The company is submitting its Annual Report for the financial year 2025-26, which includes the Business Responsibility and Sustainability Report and the Notice of AGM. These documents are being sent electronically to shareholders and are also available on the company's website. The report highlights the company's theme 'Accelerate Intelligence, Embrace Excellence' and its commitment to innovation and sustainability within the evolving pharmaceutical landscape. The AGM notice will detail remote e-voting procedures and participation instructions.

RPG Life Sciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from Wednesday, July 1, 2026, and will remain in effect until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to consider these results will be communicated separately. This measure is in line with SEBI regulations and the company's internal code of conduct to prevent insider trading.